Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway
10.12092/j.issn.1009-2501.2023.01.015
- Author:
Chang SHEN
1
;
Kelong AI
1
;
Changping HU
1
Author Information
1. Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Key Laboratory of Cardiovascular Research of Hunan Province
- Publication Type:Journal Article
- Keywords:
hypoxia-inducible factor-1;
pulmonary artery adventitial fibroblasts;
pulmonary artery endothelial cells;
pulmonary artery smooth muscle cells;
pulmonary hypertension
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(1):114-120
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary hypertension (PH) is a rare and severe progressive disease. It results from hypertrophic remodeling of distal pulmonary arterioles that increases pulmonary arterial pressure and pulmonary vascular resistance in the absence of left heart, pulmonary parenchymal, or thromboembolic disease. Hypoxia-inducible factor-1 (HIF-1) regulates a large number of genes related to the occurrence and development of PH, and induces pulmonary angiogenesis, cell proliferation and migration, cellular energy metabolism and utilization. HIF-1 is an important component of the pathogenesis of hypoxic PH and plays an important role in driving the pathological process of pulmonary vascular and right ventricular remodeling. This article systematically elucidated the role and regulation of HIF-1 in hypoxic PH and its potential in targeted therapy of PH.
